Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
Ronald G. Steis, John Edward McKnight, Walter J. Urba(Providence Portland Medical Center), Louis A. VanderMolen, Robin Lin Miller(Michigan State University), John W. Smith(SUNY Upstate Medical University), Michael A. Bookman(National Cancer Institute), Edward D. Crum, Jeffrey W. Clark(Massachusetts General Hospital), Suzanne K. Beckner
Cited by 106
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k